MedPath

TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER

TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER logo
🇺🇸United States
Ownership
Private, Subsidiary
Established
1969-01-01
Employees
1K
Market Cap
-
Website
http://www.ttuhsc.edu

Clinical Trials

91

Active:3
Completed:45

Trial Phases

5 Phases

Early Phase 1:5
Phase 1:14
Phase 2:6
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (71 trials with phase data)• Click on a phase to view related trials

Not Applicable
33 (46.5%)
Phase 1
14 (19.7%)
Phase 4
13 (18.3%)
Phase 2
6 (8.5%)
Early Phase 1
5 (7.0%)

Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients

Phase 4
Not yet recruiting
Conditions
Orthopedic Trauma Surgery Patients
Postoperative Pain
Opioid Use
Post-traumatic Stress Disorder (PTSD)
Depression
Interventions
Drug: standard general anesthesia
First Posted Date
2025-04-01
Last Posted Date
2025-07-03
Lead Sponsor
Texas Tech University Health Sciences Center
Target Recruit Count
90
Registration Number
NCT06903819
Locations
🇺🇸

Texas Tech University Health Sciences Center Lubbock, Lubbock, Texas, United States

🇺🇸

University Medical Center, Lubbock, Texas, United States

Early Childhood Obesity Among Rural Residents of West Texas

Not Applicable
Not yet recruiting
Conditions
Obesity
First Posted Date
2025-02-17
Last Posted Date
2025-02-17
Lead Sponsor
Texas Tech University Health Sciences Center
Target Recruit Count
480
Registration Number
NCT06831097
Locations
🇺🇸

Texas Tech University Health Sciences Center, Lubbock, Texas, United States

Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy

Early Phase 1
Recruiting
Conditions
Post Operative Pain
Interventions
First Posted Date
2024-04-05
Last Posted Date
2025-03-21
Lead Sponsor
Texas Tech University Health Sciences Center
Target Recruit Count
130
Registration Number
NCT06349772
Locations
🇺🇸

Texas Tech University Health Sciences Center, Lubbock, Texas, United States

Starvation in the Treatment of Diabetic Ketoacidosis

Not Applicable
Conditions
Diabetes Mellitus
Diabetic Ketoacidosis
First Posted Date
2023-12-29
Last Posted Date
2024-11-06
Lead Sponsor
Texas Tech University Health Sciences Center
Target Recruit Count
200
Registration Number
NCT06186245
Locations
🇺🇸

University Medical Center, Lubbock, Texas, United States

Life Story Questionnaire and Physical Therapy Participation

Not Applicable
Recruiting
Conditions
Dementia Alzheimers
First Posted Date
2023-04-25
Last Posted Date
2023-05-31
Lead Sponsor
Texas Tech University Health Sciences Center
Target Recruit Count
60
Registration Number
NCT05827276
Locations
🇺🇸

Peachtree Place (Dementia care facility), Weatherford, Texas, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 19
  • Next

News

Study Reveals Significant Pregnancy Risks for Minority Women with Cancer

New research from Texas Tech University Health Sciences Center shows racial and ethnic minority women with cancer face up to 40% higher risk of adverse pregnancy outcomes compared to their white counterparts.

Breakthrough Medications Show Promise in Reducing Lipoprotein(a) Levels by Up to 90%

Two novel therapies - oral muvalaplin and injectable zerlasiran - demonstrate remarkable efficacy in lowering lipoprotein(a) levels by 80-90% with minimal side effects in clinical trials.

Optimizing Kidney Cancer Treatment: Keytruda, Inlyta, and Novel Approaches for Non-Clear Cell RCC

• Considerations for discontinuing Keytruda (pembrolizumab) and Inlyta (axitinib) after two years involve balancing recurrence risk and side effects, necessitating individualized patient-physician discussions. • For non-clear cell chromophobe renal cell carcinoma, IO-TKI combinations like Lenvima (lenvatinib) plus Keytruda or Cabometyx (cabozantinib) plus Opdivo (nivolumab) show promise, with treatment choice depending on approval status. • Managing fatigue and chronic kidney disease in RCC patients requires investigating reversible causes and employing supportive measures, with nephrologist involvement for significant renal impairment.

© Copyright 2025. All Rights Reserved by MedPath